跳转至内容
Merck
CN
  • Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues.

Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues.

Nature communications (2017-12-01)
Ilya Y Shadrin, Brian W Allen, Ying Qian, Christopher P Jackman, Aaron L Carlson, Mark E Juhas, Nenad Bursac
摘要

Despite increased use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, functional heart tissues for human therapy are lacking. Here we present a "Cardiopatch" platform for 3D culture and maturation of hiPSC-CMs that after 5 weeks of differentiation show robust electromechanical coupling, consistent H-zones, I-bands, and evidence for T-tubules and M-bands. Cardiopatch maturation markers and functional output increase during culture, approaching values of adult myocardium. Cardiopatches can be scaled up to clinically relevant dimensions, while preserving spatially uniform properties with high conduction velocities and contractile stresses. Within window chambers in nude mice, cardiopatches undergo vascularization by host vessels and continue to fire Ca

材料
产品编号
品牌
产品描述

Sigma-Aldrich
(−)-II型肌球蛋白, solid, synthetic
Sigma-Aldrich
凝血酶 来源于牛血浆, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
Sigma-Aldrich
纤维蛋白原 来源于人类血浆, 35-65% protein (≥90% of protein is clottable).
Sigma-Aldrich
聚二甲基硅氧烷, viscosity 1.0 cSt (25 °C)